Invesco Ltd. Acquires 67,130 Shares of Ginkgo Bioworks Holdings, Inc. $DNA

Key Points

• Invesco Ltd. increased its stake in Ginkgo Bioworks by 252.8%, acquiring a total of 93,684 shares valued at $534,000.
• Ginkgo Bioworks reported earnings of ($1.10) per share for the last quarter, exceeding analysts' expectations of ($1.44), with revenues of $49.60 million.
• The company has a market capitalization of $658.01 million and a current share price of $11.12, with a year high of $16.85 and a low of $5.00.

Invesco Ltd. lifted its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 252.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,684 shares of the company's stock after buying an additional 67,130 shares during the quarter. Invesco Ltd. owned about 0.16% of Ginkgo Bioworks worth $534,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC grew its stake in shares of Ginkgo Bioworks by 353.6% in the fourth quarter. Barclays PLC now owns 54,166 shares of the company's stock valued at $531,000 after buying an additional 42,224 shares in the last quarter. Forbes J M & Co. LLP grew its stake in shares of Ginkgo Bioworks by 56.0% in the first quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock valued at $6,239,000 after buying an additional 392,832 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Ginkgo Bioworks by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company's stock valued at $412,000 after buying an additional 5,746 shares in the last quarter. Northern Trust Corp grew its stake in shares of Ginkgo Bioworks by 11.5% in the fourth quarter. Northern Trust Corp now owns 94,876 shares of the company's stock valued at $932,000 after buying an additional 9,791 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Ginkgo Bioworks by 14.4% in the first quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company's stock valued at $150,000 after buying an additional 3,331 shares in the last quarter. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Stock Up 1.7%

Shares of DNA traded up $0.17 during midday trading on Thursday, reaching $10.46. 1,981,822 shares of the stock were exchanged, compared to its average volume of 1,545,899. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $16.85. The company has a market cap of $619.23 million, a P/E ratio of -1.78 and a beta of 1.50. The stock's 50 day simple moving average is $12.06 and its 200 day simple moving average is $9.26.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.44) by $0.34. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%.The company had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on DNA. BTIG Research lifted their price objective on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a "sell" rating in a research report on Monday, August 25th. Wall Street Zen raised shares of Ginkgo Bioworks from a "sell" rating to a "hold" rating in a research report on Saturday, August 30th. Finally, Cowen reaffirmed a "buy" rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $9.50.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.